Curis (CRIS) Q2 2026 earnings summary

Executive summary

• Focused on developing emavusertib, an IRAK4/FLT3 inhibitor, with ongoing Phase 1/2 studies in PCNSL and CLL; monotherapy and AML studies are substantially complete.

• Emavusertib has received Orphan Drug Designation from the FDA and European Commission for multiple indications.

• Company completed a public offering in August 2026, raising approximately $4.8 million in net proceeds.

Financial highlights

• Net loss was $8.6 million for Q2 2026 and $32.8 million for the six months ended June 30, 2026, compared to $8.6 million and $19.2 million for the same periods in 2025.

• Cash and cash equivalents were $5.1 million as of June 30, 2026.

• Operating expenses for the six months ended June 30, 2026, were $21.5 million, down from $23.5 million year-over-year.

• Research and development expenses decreased 18% year-over-year for the six-month period, primarily due to lower employee, clinical, and manufacturing costs.

• General and administrative expenses increased 10% year-over-year for the six-month period, mainly due to costs associated with the January 2026 PIPE Financing and higher legal costs.

Outlook and guidance

• Current cash and recent offering proceeds are expected to fund operations into Q4 2026; substantial additional capital will be required to continue development and operations beyond that.

• Company does not expect to achieve profitability in the foreseeable future and will need to seek additional funding through equity, collaborations, or strategic transactions.